文献速递药物不良反应与药物警戒

接种mRNA与病毒载体COVID-19疫苗后卡介苗瘢痕复活的病例系列

A case series of bacillus Calmette-Guérin scar reactivation after administration of both mRNA and viral vector COVID-19 vaccines.
PubMed 文献 · Br J Clin Pharmacol · 2023-02-10

该病例系列基于荷兰药物警戒中心Lareb自发报告系统,收集2021年1月以来接种COVID-19疫苗后出现卡介苗(BCG)瘢痕复活的22例报告。其中20例涉及mRNA疫苗(Moderna 14例、Pfizer 6例),2例涉及病毒载体疫苗AstraZeneca。反应以红斑和疼痛最常见,炎症大小1.5–5 cm,首次接种后中位起病时间7天,第二剂或加强剂后2天,均未治疗,为自限性非严重反应。

要点

  • 接种mRNA和病毒载体COVID-19疫苗后均可出现BCG瘢痕复活。
  • 表现为红斑、疼痛,炎症大小1.5–5 cm,中位起病2–7天。
  • 该反应为自限性、非严重,无需治疗。

核心结论

  • BCG瘢痕复活是接种mRNA和病毒载体COVID-19疫苗后可发生的非严重、自限性反应。
  • 确切机制尚不明确,但提示热休克蛋白65可能参与。

研究设计与样本

  • 病例系列,数据来自荷兰药物警戒中心Lareb自发报告系统。
  • 对检测到BCG瘢痕复活的病例报告进行描述性分析。

主要发现

  • 2021年1月COVID-19疫苗接种活动开始以来,Lareb共收到22例接种COVID-19疫苗后BCG复活的病例报告。
  • 20例涉及mRNA COVID-19疫苗Moderna(14例)和Pfizer(6例),2例涉及病毒载体COVID-19疫苗AstraZeneca。
  • 红斑和疼痛是最常报告的症状,炎症大小在1.5至5 cm之间。
  • BCG瘢痕复活在第二剂或加强剂COVID-19疫苗接种后中位起病时间为2天,而首次COVID-19疫苗接种后中位起病时间为7天。
  • 所有BCG瘢痕复活均未接受治疗。

临床怎么用

  • 临床药学智能体医生应识别接种COVID-19疫苗后BCG瘢痕复活为自限性非严重反应,避免不必要的治疗。

局限性

  • 数据来源于自发报告系统,可能存在报告偏倚和漏报。
  • 病例系列无法确定因果关系或确切机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Reactivation of the scar resulting from intradermal injection of bacillus Calmette-Guérin (BCG) is a common specific reaction in Kawasaki's disease. It has also sporadically been associated with viral infections, multisystem inflammatory syndrome in children, influenza vaccination and mRNA COVID-19 vaccination. In this case series, characteristics of BCG scar reactivation after different COVID-19 vaccinations are presented and possible mechanisms are discussed. METHODS: Data were collected from the spontaneous reporting system of the Netherlands Pharmacovigilance Centre Lareb. Descriptives were made for the case reports in which a BCG scar reactivation was detected. RESULTS: Since the start of the COVID-19 vaccination campaign in January 2021, the Netherlands Pharmacovigilance Centre Lareb has received 22 case reports of BCG reactivation after vaccination with a COVID-19 vaccine. In 20 case reports, it concerned mRNA COVID-19 vaccines Moderna (14) and Pfizer (6). In two case reports, the viral vector COVID-19 vaccine AstraZeneca was administered. Erythema and pain were the most frequently reported symptoms and the size of the inflammation was between 1.5 and 5 cm. BCG scar reactivation occurred with a median time to onset of 2 days after the second or booster COVID-19 vaccination, whereas the median time to onset was 7 days after the first COVID-19 vaccination. None of the BCG scar reactivations were treated. CONCLUSIONS: The exact mechanism of the occurrence of BCG scar reactivation remains unknown, but involvement of heat shock protein 65 is suggested. BCG scar reactivation is a nonserious, self-limiting reaction that can occur after vaccination with both mRNA and viral vector COVID-19 vaccines.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. van Balveren L, van Puijenbroek EP, Davidson L, et al. A case series of bacillus Calmette-Guérin scar reactivation after administration of both mRNA and viral vector COVID-19 vaccines. Br J Clin Pharmacol. 2023. PMID: 36717367. doi:10.1111/bcp.15678

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。